Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Menée sur 1 253 patients atteints d'un cancer du côlon ou du rectum et inclus dans deux études de cohorte comportant des professionnels de santé, cette étude évalue, du point de vue de la survie, la valeur pronostique de la présence d'une mutation du gène BRAF en fonction du statut des microsatellites (stable ou instable)
BRAF mutation in colorectal cancer is associated with microsatellite instability (MSI) through its relationship with high-level CpG island methylator phenotype (CIMP) and MLH1 promoter methylation. MSI and BRAF mutation analyses are routinely used for familial cancer risk assessment. To clarify clinical outcome associations of combined MSI/BRAF subgroups, we investigated survival in 1253 rectal and colon cancer patients within the Nurses’ Health Study and Health Professionals Follow-up Study with available data on clinical and other molecular features, including CIMP, LINE-1 hypomethylation, and KRAS and PIK3CA mutations. Compared with the majority subtype of microsatellite stable (MSS)/BRAF–wild-type, MSS/BRAF-mutant, MSI-high/BRAF-mutant, and MSI-high/BRAF–wild-type subtypes showed multivariable colorectal cancer-specific mortality hazard ratios of 1.60 (95% confidence interval [CI] =1.12 to 2.28; P = .009), 0.48 (95% CI = 0.27 to 0.87; P = .02), and 0.25 (95% CI = 0.12 to 0.52; P < .001), respectively. No evidence existed for a differential prognostic role of BRAF mutation by MSI status (P interaction > .50). Combined BRAF/MSI status in colorectal cancer is a tumor molecular biomarker for prognosic risk stratification.
Journal of the National Cancer Institute , résumé, 2013